ConductScience.org, home

Paper37348019

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Tolaney SM and 15 others. J Clin Oncol, 2023. Cited by 70 papers, by iCite.

Cite this record

ConductScience Library. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Papers, record 37348019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37348019

Download JSON
Disease
breast cancer1,032 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
70
iCite
Relative citation ratio, by iCite
4.73
iCite
Revised in PubMed
2026-09-21
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tolaney SMSara Mhttps://orcid.org/0000-0002-5940-8671
2Chan AArlenehttps://orcid.org/0000-0003-2135-2286
3Petrakova KKatarina
4Delaloge SSuzettehttps://orcid.org/0000-0003-2106-9165
5Campone MMario
6Iwata HHirojihttps://orcid.org/0000-0002-0242-4718
7Peddi PFParvin Fhttps://orcid.org/0000-0002-8459-9828
8Kaufman PAPeter Ahttps://orcid.org/0000-0003-3677-6807
9De Kermadec EElisabeth
10Liu QQianying
11Cohen PPatrickhttps://orcid.org/0009-0008-1187-1123
12Paux GGautierhttps://orcid.org/0000-0003-3002-6351
13Wang LLei
14Ternès NNils
15Boitier EEric
16Im SASeock-Ahhttps://orcid.org/0000-0002-5396-6533

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Humans
Female
Receptors, Estrogen
Antineoplastic Combined Chemotherapy Protocols
Erb-b2 Receptor Tyrosine Kinases

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04059484Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerResultsYes

Source ClinicalTrials.gov

Download CSV of trials

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128816986Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.Medicine (Baltimore)2017https://conductscience.org/library/papers/28816986PubMed
225380844Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.Cancer Discov2015https://conductscience.org/library/papers/25380844PubMed
327174596Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.Nat Commun2016https://conductscience.org/library/papers/27174596PubMed
430206110The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.Cancer Discov2018https://conductscience.org/library/papers/30206110PubMed
529289555Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.Pharmacol Ther2018https://conductscience.org/library/papers/29289555PubMed
630555626DNA damage repair defects as a new class of endocrine treatment resistance driver.Oncotarget2018https://conductscience.org/library/papers/30555626PubMed
7329795135th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).Ann Oncol2020https://conductscience.org/library/papers/32979513PubMed
820632084Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).Breast Cancer Res Treat2010https://conductscience.org/library/papers/20632084PubMed
926947331
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Lancet Oncol2016https://conductscience.org/library/papers/26947331PubMed
1035584336
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol2022https://conductscience.org/library/papers/35584336PubMed
1129860922Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.J Clin Oncol2018https://conductscience.org/library/papers/29860922PubMed
1228580882MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.J Clin Oncol2017https://conductscience.org/library/papers/28580882PubMed
1334392831ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Breast Cancer Res2021https://conductscience.org/library/papers/34392831PubMed
1419097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1527908454Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.Lancet2016https://conductscience.org/library/papers/27908454PubMed
1630205045The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Cancer Cell2018https://conductscience.org/library/papers/30205045PubMed
1731091374Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med2019https://conductscience.org/library/papers/31091374PubMed
1827269946Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.J Clin Oncol2016https://conductscience.org/library/papers/27269946PubMed
1933538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
2038729567A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.Ann Oncol2024https://conductscience.org/library/papers/38729567PubMed

See all 30 referencesDownload CSV of references

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.

PMIDTitleJournalYearIn PapersSource
42948694Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2- advanced breast cancer.Acta Pharm Sin B2026https://conductscience.org/library/papers/42948694PubMed
42927396Retrospective Analysis of Real-World Elacestrant Use in Two Large Austrian Cancer Centers.Breast Care (Basel)2026https://conductscience.org/library/papers/42927396PubMed
42816507ERα Micromap (µMap) proximity labeling reveals fulvestrant mechanisms.Nat Commun2026https://conductscience.org/library/papers/42816507PubMed
42761341Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.Explor Target Antitumor Ther2026https://conductscience.org/library/papers/42761341PubMed
42755923Oral selective estrogen receptor degraders in ER+/HER2- breast cancer: a systematic review with pooled analysis of metastatic randomized trials and narrative synthesis of adjuvant evidence.Front Oncol2026https://conductscience.org/library/papers/42755923PubMed
42657161Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.Front Oncol2026https://conductscience.org/library/papers/42657161PubMed
42510955Targeting Estrogen Receptor for Breast Cancer.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42510955PubMed
42449621
Oral Estrogen Receptor Degraders Compared to Standard Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Cancers (Basel)2026https://conductscience.org/library/papers/42449621PubMed
42445743Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer.Drug Des Devel Ther2026https://conductscience.org/library/papers/42445743PubMed
42401911Sex differences in non-reproductive cancers: mechanistic roles of sex-hormone signaling.Cell Commun Signal2026https://conductscience.org/library/papers/42401911PubMed
42311745Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals.Cureus2026https://conductscience.org/library/papers/42311745PubMed
42045295Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.NPJ Breast Cancer2026https://conductscience.org/library/papers/42045295PubMed
41999452Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Curr Treat Options Oncol2026https://conductscience.org/library/papers/41999452PubMed
41917040Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer.Nat Commun2026https://conductscience.org/library/papers/41917040PubMed
41704390Allosteric Induction of Estrogen Receptor Ligand Binding Domain Tetramerization by a Distinct Complete Estrogen Receptor Antagonist.ACS Med Chem Lett2026https://conductscience.org/library/papers/41704390PubMed
41654790Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.BMC Cancer2026https://conductscience.org/library/papers/41654790PubMed
41572375Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.Breast Cancer Res2026https://conductscience.org/library/papers/41572375PubMed
41420679CDK4/6 inhibitor rechallenge therapy in advanced breast cancer.Discov Oncol2025https://conductscience.org/library/papers/41420679PubMed
41241883Advances and challenges of estrogen receptor-targeted agents in breast cancer.Arch Pharm Res2025https://conductscience.org/library/papers/41241883PubMed
41097702Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/41097702PubMed

See all 46 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs6

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
EXEMESTANECHEMBL1200374Results1https://conductscience.org/library/drugs/CHEMBL1200374ChEMBL
FULVESTRANTCHEMBL1358Results1https://conductscience.org/library/drugs/CHEMBL1358ChEMBL
ANASTROZOLECHEMBL1399Results1https://conductscience.org/library/drugs/CHEMBL1399ChEMBL
LETROZOLECHEMBL1444Results1https://conductscience.org/library/drugs/CHEMBL1444ChEMBL
AMCENESTRANTCHEMBL4475463Results1https://conductscience.org/library/drugs/CHEMBL4475463ChEMBL
TAMOXIFENCHEMBL83Results1https://conductscience.org/library/drugs/CHEMBL83ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37348019

GET https://conductscience.org/api/papers/v1/37348019/references?page=2